NURO צמיחה צפויה ברווח נקי למניה השנה neurometrix.com
Competition from mass-market gadgets and weak commercialization are eroding the uniqueness of NeuroMetrix, Inc. (NURO). The percentage deviation of EPS from the previous year on the GURU.Markets chart confirms a trend where the 0.00 metric determines this level. NeuroMetrix, Inc. (NURO) is developing Quell bioelectronics and pain management software, although pricing pressure in retail is limiting the cost of their specialized neurostimulators.
פילוחים אנליטיים ודוחות נתונים של חברת NeuroMetrix, Inc. (NURO)
The expansion of Quell wearable devices into pharmacy chains and the insurance sector is directly reflected in the current year-over-year EPS dynamics for NeuroMetrix, Inc. (NURO). This indicator measures the percentage change in net income per share, demonstrating the business's monetization efficiency relative to the previous year. The positive trend confirms an increase in the real return on equity, which is critical for assessing the fundamental value of NeuroMetrix, Inc. (NURO).
